The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes with Benjamin Derman, MD
Spotify%20--%3e%3csvg%20version='1.1'%20id='Livello_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20width='300px'%20height='300px'%20viewBox='0%200%20300%20300'%20enable-background='new%200%200%20300%20300'%20xml:space='preserve'%3e%3cg%20id='XMLID_632_'%3e%3clinearGradient%20id='XMLID_2_'%20gradientUnits='userSpaceOnUse'%20x1='150'%20y1='0'%20x2='150'%20y2='300'%3e%3cstop%20offset='0'%20style='stop-color:%23F452FF'/%3e%3cstop%20offset='1'%20style='stop-color:%23832BC1'/%3e%3c/linearGradient%3e%3cpath%20id='XMLID_662_'%20fill-rule='evenodd'%20clip-rule='evenodd'%20fill='url(%23XMLID_2_)'%20d='M294.1,260c-2.9,7.4-9.6,17.8-19.2,25.2%20c-5.5,4.2-12.1,8.3-21.1,11c-9.6,2.9-21.5,3.8-36.3,3.8h-135c-14.8,0-26.6-1-36.3-3.8c-9-2.7-15.6-6.7-21.1-11%20c-9.5-7.3-16.3-17.8-19.2-25.2C0.1,245.1,0,228.2,0,217.5l0,0v-135l0,0C0,71.8,0.1,54.9,5.9,40c2.9-7.4,9.6-17.8,19.2-25.2%20c5.5-4.2,12.1-8.3,21.1-11C55.9,1,67.7,0,82.5,0l0,0h135l0,0c14.8,0,26.6,1,36.3,3.8c9,2.7,15.6,6.7,21.1,11%20c9.5,7.3,16.3,17.8,19.2,25.2c5.9,14.9,5.9,31.9,5.9,42.5v135C300,228.2,299.9,245.1,294.1,260z'/%3e%3cg%3e%3cpath%20id='XMLID_657_'%20fill='%23FFFFFF'%20d='M175.7,181.1c-0.4-3.6-1.6-6.2-4-8.6c-4.5-4.7-12.4-7.8-21.7-7.8c-9.3,0-17.2,3-21.7,7.8%20c-2.3,2.5-3.6,5-4,8.6c-0.8,7-0.3,13,0.5,22.7c0.8,9.2,2.3,21.5,4.2,33.9c1.4,8.9,2.5,13.7,3.5,17.1c1.7,5.6,7.8,10.4,17.5,10.4%20c9.7,0,15.9-4.9,17.5-10.4c1-3.4,2.1-8.2,3.5-17.1c1.9-12.5,3.4-24.7,4.2-33.9C176.1,194.1,176.5,188.1,175.7,181.1z'/%3e%3cpath%20id='XMLID_655_'%20fill='%23FFFFFF'%20d='M174.6,130.1c0,13.6-11,24.6-24.6,24.6s-24.6-11-24.6-24.6c0-13.6,11-24.6,24.6-24.6%20S174.6,116.6,174.6,130.1z'/%3e%3cpath%20id='XMLID_653_'%20fill='%23FFFFFF'%20d='M149.7,33.2C92.3,33.4,45.3,80,44.5,137.4c-0.6,46.5,29.1,86.3,70.6,100.9%20c1,0.4,2-0.5,1.9-1.5c-0.5-3.6-1.1-7.2-1.5-10.8c-0.2-1.3-1-2.3-2.1-2.9c-32.8-14.3-55.7-47.2-55.3-85.3%20c0.5-50,41.3-90.7,91.2-91.1c51.1-0.4,92.8,41,92.8,92c0,37.7-22.8,70.1-55.3,84.4c-1.2,0.5-2,1.6-2.1,2.9%20c-0.5,3.6-1,7.2-1.5,10.8c-0.2,1.1,0.9,1.9,1.9,1.5c41.1-14.4,70.6-53.6,70.6-99.6C255.5,80.5,208,33.1,149.7,33.2z'/%3e%3cpath%20id='XMLID_651_'%20fill='%23FFFFFF'%20d='M147.3,68.2c-37.4,1.4-67.4,32.3-67.9,69.7c-0.3,24.6,12,46.4,30.9,59.3%20c0.9,0.6,2.2-0.1,2.2-1.2c-0.3-4.3-0.3-8.1-0.1-12.1c0.1-1.3-0.4-2.5-1.4-3.4c-11.5-10.8-18.5-26.2-18.1-43.2%20c0.8-30,24.9-54.4,54.9-55.6c32.6-1.3,59.4,24.9,59.4,57.1c0,16.4-7,31.2-18.1,41.7c-0.9,0.9-1.4,2.1-1.4,3.4%20c0.2,3.9,0.1,7.7-0.1,12c-0.1,1.1,1.2,1.9,2.2,1.2c18.6-12.7,30.9-34.2,30.9-58.4C220.8,98.9,187.5,66.6,147.3,68.2z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Apple Podcasts
YoutubeMRD testing is coming of age in both clinical trials and in the myeloma clinic. Ben Derman, MD of the University of Chicago shares MRD basics, how MRD testing is being evaluated by the FDA as a new clinical trial end point, and clinical trials that are using MRD testing. It is too soon to tell, but over time, perhaps in the future MRD testing can inform patients about how well they may do on treatment, and when to start or stop therapy based on the results.
Thanks to our episode sponsor:
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Benjamin Derman, MD
Benjamin Derman, MD, specializes in hematology and oncology. Dr. Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He also diagnoses and treats cancerous conditions and uses the most innovative techniques, including CAR T-cell therapy and stem cell transplantation to deliver long-term success for his patients. Along with his clinical practice, Dr. Derman remains committed to research. Currently, he is focused on identifying strategies that can lead to a possible cure for multiple myeloma, including using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making. Dr. Derman is also investigating new methods and therapies designed to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients. His work has been published in several peer-reviewed journals, including the Journal of Immunotherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia and Lymphoma and British Journal of Haematology.
